01 Shift toward Hypophosphatemia-monitored IV Iron Administration Protocols Hospitals are increasingly implementing phosphate-monitoring protocols before administering high-dose iron therapies, which showcases a major IV and oral iron drugs market trend. Hospitals are implementing such protocols, particularly ferric carboxymaltose, due to rising cases of treatment-induced hypophosphatemia. Nephrology and oncology pathways now include routine serum phosphate testing during repeat infusions to reduce osteomalacia, fatigue, and muscle weakness risks in chronic anemia patients. This trend is shifting physician preference toward ferric derisomaltose, which demonstrates lower hypophosphatemia incidence. Specialty infusion centers are also integrating electrolyte-monitoring software with anemia management systems, making safety-focused formulation selection a competitive factor within the iron drugs market.
02 Expansion of Post-bariatric Surgery Iron Maintenance Therapies The growing number of sleeve gastrectomy and gastric bypass procedures is increasing long-term IV and oral iron drugs market demand for malabsorption-related anemia. Conventional ferrous sulfate products show limited absorption after bariatric surgery, driving adoption of sucrosomial and liposomal iron formulations with improved intestinal uptake. Bariatric clinics are increasingly prescribing cyclic IV iron regimens alongside micronutrient monitoring to prevent recurrent ferritin depletion. IV and oral iron drug manufacturers are also introducing low-volume dosing approaches for ambulatory bariatric care settings, where repeated anemia management has become essential in post-surgical metabolic treatment programs.
01 Rising Preference for Dextran-free IV Iron Formulations and Growing Therapeutic Use in Inflammatory Gastrointestinal Disorders Drive Market Growing demand for safer and better-tolerated iron therapies is driving the adoption of dextran-free IV iron drugs in hospitals and specialty care settings. Unlike conventional iron dextran formulations, newer products such as ferric carboxymaltose and iron sucrose offer a lower risk of hypersensitivity reactions, improved patient compliance, and the ability to deliver higher iron doses in shorter infusion times, making them increasingly preferred in nephrology, oncology, and surgical care applications. Demand is rising particularly in outpatient infusion centers and chronic kidney disease treatment programs, where healthcare providers seek faster and safer iron replenishment therapies. For example, increasing clinical use of Injectafer in anemia management reflects the growing preference for high-dose dextran-free IV iron formulations across hospital networks and specialty care facilities.A major IV and oral iron drugs market driver is the increasing prevalence of inflammatory gastrointestinal disorders, as anemia remains a common complication in patients with chronic intestinal inflammation and impaired nutrient absorption. Conditions such as Crohn's disease and ulcerative colitis frequently lead to iron deficiency due to chronic blood loss and reduced iron absorption, increasing the need for long-term iron replacement therapy. Healthcare providers are increasingly preferring IV iron formulations for moderate-to-severe cases because they offer faster iron restoration and better tolerability compared to conventional oral therapies. Growing clinical emphasis on anemia management within gastroenterology treatment protocols is therefore strengthening demand for advanced iron therapies across hospitals and specialty digestive care centers.
01 High Risk of IV Iron-induced Hypophosphatemia and Declining Use of Conventional Ferrous Salts Restrain Market Increasing clinical concern regarding IV iron-induced hypophosphatemia linked with ferric carboxymaltose therapies is restraining market growth. Repeated high-dose infusions can trigger severe phosphate depletion, osteomalacia, muscle weakness, bone pain, and prolonged fatigue, increasing the need for continuous laboratory monitoring and follow-up visits. Many hospitals now require serum phosphate testing before repeat dosing, adding treatment complexity and operational costs. These safety concerns are reducing physician preference for certain IV formulations and slowing adoption across outpatient anemia management programs and infusion care settings globally.Poor intestinal absorption of conventional ferrous sulfate and ferrous fumarate formulations is a major IV and oral iron drugs market restraint. In patients with inflammatory bowel disease, chronic inflammation, bariatric surgery history, or elevated hepcidin levels, oral iron absorption remains significantly reduced, limiting therapeutic effectiveness. This frequently results in persistent anemia despite prolonged supplementation and increases switching toward costly IV therapies or advanced liposomal formulations. Physicians are becoming less reliant on standard oral iron products for complex anemia cases, reducing prescription continuity and limiting growth potential for conventional oral iron drug manufacturers globally.
01 Growing Use of Iron Therapy in Heart Failure Management and Expansion of Outpatient Infusion Centers Offer Growth Opportunities Increasing recognition of iron deficiency in chronic heart failure patients is creating new opportunities for IV and oral iron drugs market growth beyond traditional anemia treatment settings. Cardiologists are increasingly using ferric carboxymaltose to improve exercise tolerance, fatigue, and hospitalization outcomes in heart failure patients with low ferritin levels. European Society of Cardiology guidelines now support IV iron supplementation in symptomatic heart failure management. Major cardiac centers are integrating iron status assessment into routine cardiovascular care pathways, expanding clinical utilization of IV iron products across cardiology departments and chronic disease management programs globally.Rapid expansion of outpatient infusion centers presents strong growth opportunities in the IV and oral iron drugs market, as manufacturers are shifting anemia care away from inpatient hospitals. In the US, over 3,000 ambulatory infusion centers are now operating, with commercial payers increasingly steering iron therapy to lower-cost outpatient settings. Studies show outpatient IV iron administration can reduce treatment costs by nearly 30-40% compared to hospital-based care. This model increases patient throughput and enables repeated dosing schedules, significantly boosting demand for ferric carboxymaltose and ferric derisomaltose in decentralized care environments globally.
In November 2025, Shield Therapeutics launched ACCRUFeR (ferric maltol) in Canada through its partnership with Kye Pharmaceuticals following Health Canada approval.
In August 2025, Viatris received US FDA approval for the first generic iron sucrose injection, USP, referencing Venofer, for the treatment of iron deficiency anemia in chronic kidney disease patients.
In August 2025, Viatris announced imminent US commercialization of single-dose vial presentations in 50 mg/2.5 mL, 100 mg/5 mL, and 200 mg/10 mL strengths.